CA2025668A1 - Use of omeprazole as an antimicrobial agent - Google Patents

Use of omeprazole as an antimicrobial agent

Info

Publication number
CA2025668A1
CA2025668A1 CA2025668A CA2025668A CA2025668A1 CA 2025668 A1 CA2025668 A1 CA 2025668A1 CA 2025668 A CA2025668 A CA 2025668A CA 2025668 A CA2025668 A CA 2025668A CA 2025668 A1 CA2025668 A1 CA 2025668A1
Authority
CA
Canada
Prior art keywords
omeprazole
antimicrobial agent
methoxy
plori
campylobacter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2025668A
Other languages
French (fr)
Other versions
CA2025668C (en
Inventor
Masaaki Tomoi
Yoshifumi Ikeda
Yoshiko Yokota
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hassle AB
Original Assignee
Masaaki Tomoi
Yoshifumi Ikeda
Yoshiko Yokota
Aktiebolaget Hassle
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=12300238&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2025668(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Masaaki Tomoi, Yoshifumi Ikeda, Yoshiko Yokota, Aktiebolaget Hassle filed Critical Masaaki Tomoi
Publication of CA2025668A1 publication Critical patent/CA2025668A1/en
Application granted granted Critical
Publication of CA2025668C publication Critical patent/CA2025668C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Abstract

Use of 5-methoxy-2-[[(4 methoxy-3,5-dimethyl-2-pyridinyl)methyl]-sulfinyl]-1H-benzimidazole or a pharmaceutically acceptable salt thereof in the treatment of infectious diseases, especially such caused by Campylobacter plori.
CA002025668A 1989-02-09 1990-02-02 Use of omeprazole as an antimicrobial agent Expired - Lifetime CA2025668C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP30311/1989 1989-02-09
JP1030311A JP2694361B2 (en) 1989-02-09 1989-02-09 Antibacterial agent

Publications (2)

Publication Number Publication Date
CA2025668A1 true CA2025668A1 (en) 1990-08-10
CA2025668C CA2025668C (en) 1998-09-15

Family

ID=12300238

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002025668A Expired - Lifetime CA2025668C (en) 1989-02-09 1990-02-02 Use of omeprazole as an antimicrobial agent

Country Status (19)

Country Link
US (1) US5093342A (en)
EP (1) EP0414847B1 (en)
JP (1) JP2694361B2 (en)
KR (1) KR0140236B1 (en)
AT (1) ATE94063T1 (en)
AU (1) AU626641B2 (en)
CA (1) CA2025668C (en)
CY (1) CY1909A (en)
DE (1) DE69003207T2 (en)
DK (1) DK0414847T3 (en)
ES (1) ES2058892T3 (en)
HK (1) HK52196A (en)
HU (1) HU205253B (en)
IE (1) IE65814B1 (en)
IL (1) IL93263A0 (en)
LV (1) LV10577B (en)
MY (1) MY111737A (en)
PH (1) PH26787A (en)
WO (1) WO1990009175A1 (en)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2066120T3 (en) * 1989-02-10 1995-03-01 Takeda Chemical Industries Ltd USE OF BENCIMIDAZOLE DERIVATIVES AS ANTIBACTERIAL AGENTS.
GB9018603D0 (en) * 1990-08-24 1990-10-10 Smith Kline French Lab Compositions
JPH06500547A (en) * 1990-09-14 1994-01-20 ビイク　グルデン　ロンベルク　ヒエーミツシエ　フアブリーク　ゲゼルシヤフト　ミツト　ベシユレンクテル　ハフツング Use of pyridylmethylsulfinyl-1H-benzimidazole derivatives for the treatment of diseases caused by Helicobacter
IS3990A (en) * 1992-04-24 1993-10-25 Ab Astra Method of mixing substances that inhibit gastric acid and bacterial degrading agent in an acidic environment
US5504082A (en) * 1992-06-01 1996-04-02 Yoshitomi Pharmaceutical Industries, Ltd. Pyridine compound and pharmaceutical compostions
WO1994013290A1 (en) * 1992-12-10 1994-06-23 Byk Gulden Lomberg Chemische Fabrik Gmbh Use of alkylthiopyridines for controlling helicobacter bacteria
US6902738B2 (en) * 1994-05-02 2005-06-07 Josman Laboratories, Inc. Topical oral dosage forms containing bismuth compounds
US5834002A (en) 1994-05-02 1998-11-10 Josman Laboratories, Inc. Chewing gum containing colloidal bismuth subcitrate
US6426085B1 (en) 1994-05-02 2002-07-30 Josman Laboratories Inc. Use of bismuth-containing compounds in topical oral dosage forms for the treatment of halitosis
US6372784B1 (en) 1995-02-07 2002-04-16 Josman Laboratories, Inc. Bismuth-containing compounds in topical dosage forms for treatment of corneal and dermal wounds
US6379651B1 (en) 1995-02-07 2002-04-30 Josman Laboratories Oral-topical dosage forms for delivering antibacterials/antibiotics to oral cavity to eradicate H. pylori as a concomitant treatment for peptic ulcers and other gastro-intestinal diseases
AU5019196A (en) * 1995-02-07 1996-08-27 Narayan Krishnarao Athanikar Concomitant treatment with oral bismuth compounds
US5708017A (en) * 1995-04-04 1998-01-13 Merck & Co., Inc. Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors
US6699885B2 (en) 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
SI9700186B (en) 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Novel pharmaceutical preparation with controlled release of active healing substances
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
DE69831504T2 (en) * 1997-12-08 2006-06-14 Altana Pharma Ag ORAL ADMINISTRATIVE FORM CONTAINING A PROTON PUMP INHIBITOR (FOR EXAMPLE, PANTOPRAZOLE)
EP1047692B1 (en) 1998-01-14 2004-07-21 The Uab Research Foundation Methods of synthesizing and screening inhibitors of bacterial nad synthetase enzyme, compounds thereof and methods of treating bacterial and microbial infections with these inhibitors
US6861448B2 (en) * 1998-01-14 2005-03-01 Virtual Drug Development, Inc. NAD synthetase inhibitors and uses thereof
US6733778B1 (en) 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6245913B1 (en) 1999-06-30 2001-06-12 Wockhardt Europe Limited Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
US6262086B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Pharmaceutical unit dosage form
US6262085B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6312712B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Method of improving bioavailability
US6780880B1 (en) 1999-08-26 2004-08-24 Robert R. Whittle FT-Raman spectroscopic measurement
US6312723B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Pharmaceutical unit dosage form
US6326384B1 (en) 1999-08-26 2001-12-04 Robert R. Whittle Dry blend pharmaceutical unit dosage form
US6316020B1 (en) 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
US6268385B1 (en) 1999-08-26 2001-07-31 Robert R. Whittle Dry blend pharmaceutical formulations
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6787342B2 (en) 2000-02-16 2004-09-07 Merial Limited Paste formulations
SE0002476D0 (en) 2000-06-30 2000-06-30 Astrazeneca Ab New compounds
EP2147679B1 (en) 2001-07-25 2014-06-25 Raptor Pharmaceutical, Inc. Compositions for blood-brain barrier transport
US20040006111A1 (en) * 2002-01-25 2004-01-08 Kenneth Widder Transmucosal delivery of proton pump inhibitors
JP2006518751A (en) * 2003-02-20 2006-08-17 サンタラス インコーポレイティッド Novel formulation for rapid and sustained suppression of gastric acid, omeprazole antacid complex-immediate release
MXPA06000529A (en) * 2003-07-18 2006-08-11 Santarus Inc Pharmaceutical composition for inhibiting acid secretion.
MXPA06000524A (en) * 2003-07-18 2006-08-11 Santarus Inc Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders.
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
WO2006116718A2 (en) 2005-04-28 2006-11-02 Proteus Biomedical, Inc. Pharma-informatics system
PL2003130T3 (en) 2006-03-10 2012-04-30 Link Genomics Inc Novel pyridine derivative having anti-helicobacter pylori activity
CN101594878A (en) 2006-09-18 2009-12-02 雷普特药品公司 By giving receptor associated protein(RAP) (RAP)-conjugate to the liver treatment of conditions
CA2665226C (en) 2006-10-05 2014-05-13 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
WO2008057802A2 (en) 2006-10-27 2008-05-15 The Curators Of The University Of Missouri Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same
WO2008075462A1 (en) 2006-12-18 2008-06-26 Arigen Pharmaceuticals, Inc. Helicobacter pylori eradicating agent having inhibitory activity on gastric acid secretion
NZ616673A (en) 2009-02-20 2014-08-29 To Bbb Holding B V Glutathione-based drug delivery system
MX2011010663A (en) 2009-04-09 2011-10-28 Arigen Pharmaceuticals Inc Pyridine thio derivative, and pharmaceutical composition which contains same and has anti-helicobacter pylori action.
ES2942923T3 (en) 2009-05-06 2023-06-07 Laboratory Skin Care Inc Dermal delivery compositions comprising complexes of active agent-calcium phosphate particles and methods of use thereof
US8992897B2 (en) 2010-01-06 2015-03-31 Elc Management Llc Skin lightening compositions
US8722026B2 (en) 2010-01-06 2014-05-13 Elc Management, Llc Skin lightening compositions
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
KR101628474B1 (en) * 2014-08-27 2016-06-08 경북대학교 산학협력단 Cosmetic composition for skin whitening comprising of omeprazole

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (en) * 1978-04-14 1979-10-15 Haessle Ab Gastric acid secretion
US4359465A (en) * 1980-07-28 1982-11-16 The Upjohn Company Methods for treating gastrointestinal inflammation
SE8301182D0 (en) * 1983-03-04 1983-03-04 Haessle Ab NOVEL COMPOUNDS
MY103790A (en) * 1987-10-30 1993-09-30 Ab Hassle Novel compound for the treatment of several bone affecting diseases

Also Published As

Publication number Publication date
KR0140236B1 (en) 1998-06-01
HUT54890A (en) 1991-04-29
ATE94063T1 (en) 1993-09-15
IE900418L (en) 1990-08-09
LV10577A (en) 1995-04-20
LV10577B (en) 1995-10-20
DK0414847T3 (en) 1993-12-13
ES2058892T3 (en) 1994-11-01
MY111737A (en) 2000-12-30
JPH02209809A (en) 1990-08-21
EP0414847A1 (en) 1991-03-06
US5093342A (en) 1992-03-03
HU901539D0 (en) 1991-02-28
PH26787A (en) 1992-10-13
HK52196A (en) 1996-03-29
JP2694361B2 (en) 1997-12-24
IL93263A0 (en) 1990-11-29
WO1990009175A1 (en) 1990-08-23
KR910700048A (en) 1991-03-13
AU626641B2 (en) 1992-08-06
DE69003207D1 (en) 1993-10-14
AU5038190A (en) 1990-09-05
IE65814B1 (en) 1995-11-15
EP0414847B1 (en) 1993-09-08
CA2025668C (en) 1998-09-15
HU205253B (en) 1992-04-28
CY1909A (en) 1990-02-02
DE69003207T2 (en) 1994-02-03

Similar Documents

Publication Publication Date Title
CA2025668A1 (en) Use of omeprazole as an antimicrobial agent
CA2284470A1 (en) New crystalline form of omeprazole
CA2011532A1 (en) Formulation
EP1020460A3 (en) The sodium salt of the (-)-enantiomer of omeprazole
CA2005986A1 (en) Benzimidazole derivative with gastric acid inhibitory effect and process for its preparation
HK1123985A1 (en) Amorphous (r)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2- pyridinyl]methyl]sulfinyl]-1h-benzimidazole as anti-ulcer agent
CA2274076A1 (en) Crystalline form of s-omeprazole
EP0392959A3 (en) Use of sertindole for the treatment of schizophrenia
EP1191025A4 (en) Crystals of benzimidazole compounds
CA2357744A1 (en) Potassium salt of (s)-omeprazole
IL98470A0 (en) Substituted benzimidazoles,process for their preparation and their pharmaceutical use
HU901085D0 (en) Process for producing substituted benzimidazole and pharmaceutical preparatives containing it
ZA989999B (en) New process for the preparation of 5-methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)1H-benzimidazole
CS734389A3 (en) 4-fluoro-2-//(4-methoxy-2-pyridyl)methyl/sulfinyl/ -1h - benzimidazole, process for its production and a pharmaceutical comprising said compound as an active component
CA2089748A1 (en) Pharmaceutical compositions containing 5-difluoromethoxy-2-[(3,4-dimethoxy-2-pyridyl) methylsulfinyl]benzimidazole and an anti-helicobacter agent for the treatment of gastrointestinal disorders
DE59001121D1 (en) Antacidatabletten.
ES2060293T3 (en) NEW ANTI-ULCER SUBSTANCE.
JO1653B1 (en) Benzimidazole process for its preparation
AR242498A1 (en) Procedure for the preparation of a pharmaceutical compound, useful for treating vascular infections or illnesses.

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry